Ivaltinostat formic (C007B-362634)

Ivaltinostat (CG-200745) formic is an orally active, potent pan- HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formicAppearance:OilIC50& Target:HDACIn Vitro:Ivaltinostat (CG-200745; 0.01-100 μM; 48 hours) formic inhibits growth of prostate cancer cells (LNCaP, DU145 and PC3 cells). Ivaltinostat (1, 10 μM; 24, 48 hours) formic increases sub-G1 population, and activates caspase-9, -3 and -8. Ivaltinostat (In Vivo:Ivaltinostat (CG-200745; p.o.; 30mg/kg/day; for 7 days) formic attenuates oxidative stress, inflammatory cytokines, and adhesion molecules in UUO kidneys. MCE has not independently confirmed the accuracy of these methods. They are for reference onlyBiological Activity:Ivaltinostat (CG-200745) formic is an orally active, potent pan- HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic.

Specifications and Purity: ≥99%

Molecular Formula: C25H35N3O6

Molecular Weight: 473.56